Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.95 +0.16 (+0.62%)

Official Closing Price Updated: 7:00 PM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗

Today 7:25 EDT

The market appears to be short-sighted.

Via The Motley Fool

Topics Intellectual Property Stocks

2 Profitable Stocks Worth Your Attention and 1 We Find Risky

Today 0:38 EDT

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

Topics Energy

Pfizer Expands Pneumococcal Vaccine Push With New Programs ↗

May 20, 2026

Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20.

Via Benzinga

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise ↗

May 20, 2026

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

Via Investor's Business Daily

Topics Stocks

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026

From Pfizer Inc.

Via Business Wire

3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗

May 18, 2026

These stocks could look like steals in a few years.

Via The Motley Fool

Topics Intellectual Property

CK Life Sciences’ Sequencio Therapeutics Appoints Emily Tan as Chief Operating Officer

May 18, 2026

HONG KONG SAR - Media OutReach Newswire - 18 May 2026 - Sequencio Therapeutics, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life...

Via MediaOutReach

Up 231%, Is RTX Proving Why It Was a Mistake for Honeywell to Replace RTX in the Dow Jones Industrial Average? ↗

May 16, 2026

Honeywell was added to the Dow for its tech focus and diversification across different end markets.

Via The Motley Fool

Topics Economy Stocks

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗

May 15, 2026

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a...

Via MarketBeat

Buy, Sell, or Hold Novo Nordisk at $46? ↗

May 15, 2026

Can Novo Nordisk thrive under intense competitive pressures?

Via The Motley Fool

My Top 3 Healthcare Stocks for May 2026 ↗

May 15, 2026

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.

Via The Motley Fool

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Via MarketBeat

Topics ETFs Intellectual Property

1 Stock Under $50 to Target This Week and 2 We Avoid

May 15, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

Via StockStory

Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How ↗

May 14, 2026

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers.

Via The Motley Fool

Topics Intellectual Property

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗

May 14, 2026

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Via The Motley Fool

Valneva Q1 Earnings Call Highlights ↗

May 13, 2026

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme...

Via MarketBeat

Topics Earnings

These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗

May 13, 2026

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for...

Via Benzinga

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗

May 13, 2026

Investors can find much better opportunities.

Via The Motley Fool

3 Struggling Stocks That Could Make for Great Contrarian Buys ↗

May 13, 2026

These stocks are facing some headwinds, but they may prove to be big winners in the long run.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 13, 2026

From Pfizer Inc.

Via Business Wire

The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call

May 13, 2026

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Manag...

Via StockStory

Topics Earnings

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer ↗

May 12, 2026

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.

Via Benzinga

Prediction: Pfizer Will Beat the Market Over the Next 5 Years ↗

May 12, 2026

It's a great time to "buy low."

Via The Motley Fool

Topics Intellectual Property

Up 373%, Is ExxonMobil Proving Why It Was a Mistake for Salesforce to Replace ExxonMobil in the Dow Jones Industrial Average? ↗

May 12, 2026

The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks.

Via The Motley Fool

Topics Stocks

Arvinas Q1 Earnings Call Highlights ↗

May 12, 2026

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline...

Via MarketBeat

Topics Earnings

Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

May 12, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

May 12, 2026

Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors

From MarketNewsUpdates.com

Via GlobeNewswire

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026

From Arvinas Inc.

Via GlobeNewswire

Is Pfizer a Buy, Sell, or Hold in 2026? ↗

May 12, 2026

Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown?

Via The Motley Fool

Topics Intellectual Property

Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe? ↗

May 12, 2026

At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.